PunjiPUNJI
Pharmaceuticals & BiotechnologySmall Cap

Kwality Pharmaceuticals Limited

KPL · ISIN: INE552U01010

Kwality Pharmaceuticals Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE552U01010.

Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.

Close (as of 2026-10-29)
₹3680.6
-0.44% today
Day Range
₹3601.1 - ₹3711.9
Market Cap (Small Cap)
₹3,819.063 Cr
Quality Score (as of 2026-06-30)
50/100

Price History

CHART

Kwality Pharmaceuticals Limited - growth of ₹100

Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.

-22441101762432026-05-082026-07-172026-08-122026-08-262026-09-092026-09-242026-10-092026-10-262026-10-29

1M

+1.08%

3M

+42.72%

6M

+133.02%

1Y

-

3Y CAGR

-

5Y CAGR

-

Earnings (TTM)

LEARN: Revenue and PAT · EPS · P/E

CHART

Kwality Pharmaceuticals Limited - revenue & profit (TTM)

Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.

0 Cr155 Cr310 Cr465 Cr620 CrQ3 FY2026Q4 FY2026Q1 FY2027
Revenue (TTM)PAT (TTM)

Technicals

3514.42

SMA (50)

2793.26

SMA (200)

-

1Y Return

10.2478

Avg Traded Value (20D, ₹Cr)

As of 2026-10-29.

Shareholding Pattern

Not available for this stock yet.

Corporate Actions

No corporate actions on record for this stock.

Recent Deals

No recent block/bulk/short-sell deals on record for this stock.

Frequently asked questions

What is Kwality Pharmaceuticals Limited's latest financial performance?

Kwality Pharmaceuticals Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹554 Cr, with a TTM profit after tax of ₹81 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹78.1.

What is Kwality Pharmaceuticals Limited's quality score?

Kwality Pharmaceuticals Limited has a Punji quality score of 50 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.

What do Kwality Pharmaceuticals Limited's technical indicators show?

As of 2026-10-29, Kwality Pharmaceuticals Limited's RSI (14-day) is 56.85 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.

Stock data · Not financial advice · Past performance does not indicate future returns